Literature DB >> 8858219

Insulin-like growth factor-I in man enhances lipid mobilization and oxidation induced by a growth hormone pulse.

T L Bianda1, M A Hussain, A Keller, Y Glatz, O Schmitz, J S Christiansen, K G Alberti, E R Froesch.   

Abstract

Growth hormone (GH) secretion is suppressed during insulin-like growth factor-I (IGF-I) administration. The aim of the study was to examine whether IGF-I alters the metabolic response to a GH pulse. Seven healthy male subjects (age 27 +/- 4 years, BMI 21.8 +/- 1.7 kg/m2) were treated with NaCl 0.9% (saline) or IGF-I (8 micrograms.kg-1.h-1) for 5 days by continuous subcutaneous infusion in a randomized, crossover fashion while receiving an isocaloric diet (30 kcal.kg-1.day-1). On the third treatment day an intravenous bolus of 0.5 U GH was administered. Forearm muscle metabolism was examined by measuring arterialized and deep venous blood samples, forearm blood flow by occlusion plethysmography and substrate oxidation by indirect calorimetry. IGF-I treatment significantly reduced insulin concentrations by 80% (p < 0.02) and C-peptide levels by 78% (p < 0.02), as assessed by area under the curve. Non-esterified fatty acid (NEFA), glycerol and 3-OH-butyrate levels were elevated and alanine concentration decreased. Forearm blood flow rose from 2.10 +/- 0.43 (saline) to 2.79 +/- 0.37 ml.100ml-1. min-1 (IGF-I) (p < 0.02). GH-pulse: 10 h after i.v. GH injection serum GH peaked at 40.9 +/- 7.4 ng/ml. GH did not influence circulating levels of total IGF-I, C-peptide, insulin or glucose, but caused a further increase in NEFA, glycerol and 3-OH-butyrate levels, indicating enhanced lipolysis and ketogenesis. This effect of GH was much more pronounced during IGF-I: NEFA rose from 702 +/- 267 (saline) and 885 +/- 236 (IGF-I) to 963 +/- 215 (saline) (p < 0.05) and 1815 +/- 586 mumol/l (IGF-I) (p < 0.02), respectively; after 5 h, 3-OH-butyrate rose from 242 +/- 234 (saline) and 340 +/- 280 (IGF-I) to 678 +/- 638 (saline) (p < 0.02) and 1115 +/- 578 mumol/l (IGF-I) (p < 0.02) respectively. After injection of GH, forearm uptake of 3-OH-butyrate was markedly elevated only in the subjects treated with IGF-I: from 44 +/- 195 to 300 +/- 370 after 20 min (p < 0.03) and to 287 +/- 91 nmol.100 ml-1. min-1 after 120 min (p < 0.02). In conclusion, the lipolytic and ketogenic response to GH was grossly enhanced during IGF-I treatment, and utilization of ketone bodies by skeletal muscle was increased.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8858219     DOI: 10.1007/bf00403916

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

1.  The source of blood samples withdrawn from deep forearm veins via catheters passed upstream from the median cubital vein.

Authors:  D R COLES; K E COOPER; R F MOTTRAM; J V OCCLESHAW
Journal:  J Physiol       Date:  1958-07-14       Impact factor: 5.182

Review 2.  Growth hormone and metabolism.

Authors:  M Press
Journal:  Diabetes Metab Rev       Date:  1988-06

3.  Dawn phenomenon in type 1 (insulin-dependent) diabetic adolescents: influence of nocturnal growth hormone secretion.

Authors:  B Beaufrère; M Beylot; C Metz; A Ruitton; R François; J P Riou; R Mornex
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

4.  Increased overnight growth hormone concentrations in diabetic compared with normal adolescents.

Authors:  J A Edge; D B Dunger; D R Matthews; J P Gilbert; C P Smith
Journal:  J Clin Endocrinol Metab       Date:  1990-11       Impact factor: 5.958

5.  A mathematical model for the determination of total area under glucose tolerance and other metabolic curves.

Authors:  M M Tai
Journal:  Diabetes Care       Date:  1994-02       Impact factor: 19.112

6.  The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics.

Authors:  J A Edge; D R Matthews; D B Dunger
Journal:  Clin Endocrinol (Oxf)       Date:  1990-12       Impact factor: 3.478

7.  Acute growth hormone effects on amino acid and lipid metabolism.

Authors:  K C Copeland; K S Nair
Journal:  J Clin Endocrinol Metab       Date:  1994-05       Impact factor: 5.958

8.  Insulin-like growth factor I inhibits glucose-stimulated insulin secretion but does not impair glucose metabolism in normal humans.

Authors:  N J Rennert; S Caprio; R S Sherwin
Journal:  J Clin Endocrinol Metab       Date:  1993-03       Impact factor: 5.958

9.  Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.

Authors:  S R Kupfer; L E Underwood; R C Baxter; D R Clemmons
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

10.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; H Walter; E R Froesch
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.